Unique Pharmacological Properties and Safety Profiles of Loop Diuretics.

Nitin Zalte, Senthilnathan Mohanasundaram, Suvro Banerjee, Gopinath Arumugam, Ashwani Mehta, Mangesh Tiwaskar, Naveen Garg, Mohan Lal, Ashok Kumar, Prasant Kumar Sahoo, Niranjan Nisty, Sharukh Golwala, Rajeev Krishna, Idris Ahmed Khan

Journal: The Journal of the Association of Physicians of India 2024;72(9S):16-18

PMID: 39291567

View on PubMed

Abstract

Loop diuretics are regarded as essential for the treatment of edematous conditions in heart failure, cirrhosis, and renal disease. The principal mechanism of action involves inhibiting the reabsorption of ions (Na+, 2Cl-, and K+) from the ascending loop of Henle. The pharmacokinetic (PK) and pharmacodynamic (PD) features of the commonly used diuretics (torsemide, furosemide, and bumetanide) influence the selection of diuretics in various disease states and dosing regimens. However, torsemide demonstrates superior PK and PD qualities, making it the preferred choice. Genetic polymorphisms must be explored to better understand the diversity of PK and PD parameters of loop diuretics between individuals.

Address: Consultant Cardiologist, Department of Cardiology, SHS Memorial Hospital and Maternity Centre, Jammu, Jammu and Kashmir, India, Corresponding Author.; Senior Consultant Cardiologist and Director, Adjunct Associate Professor, Department of Interventional Cardiology, Apollo Hospital, Apollo Hospitals Educational & Research Foundation (AHERF), Bhubaneswar, Odisha, India.; Consultant Physician and Diabetologist, Department of Medicine, Shilpa Medical Research Centre, Mumbai, Maharashtra, India.; Consultant Cardiologist, Department of Cardiology, Shree Basavalingappa Nisty Memorial Heart Center, Kalaburagi, Karnataka, India.; Senior Consultant Cardiologist, Department of Cardiology, Sir H N Reliance Foundation Hospital and Research Centre, Mumbai, Maharashtra, India.; Senior Consultant Interventional Cardiologist, Department of Cardiology, Apollo Multispeciality Hospitals, Kolkata, West Bengal, India.; Senior Consultant Interventional Cardiologist, Department of Cardiology, Mediversal Hospital, Patna, Bihar, India.; Senior Consultant Cardiologist and Director, Department of Cardiology, Heart Failure Program, Sir Ganga Ram Hospital, Delhi, India.; Senior Consultant Interventional Cardiologist, Department of Cardiology, Patna Medical College and Hospital, Patna, Bihar, India.; Professor, Department of Cardiology, Sanjay Gandhi Postgraduate Institute of Medical Sciences, Lucknow, Uttar Pradesh, India.; Interventional Cardiologist, Department of Cardiology, Sri Sanjeevi Hospital, Kallakurichi, Tamil Nadu, India.; Senior Consultant Interventional Cardiologist, Department of Cardiology, Bombay Hospital, Indore, Madhya Pradesh, India.; Senior Team Lead, Medical Affairs, Cipla Ltd., Mumbai, Maharashtra, India.; Country Head; Medical Affairs, Cipla Ltd., Mumbai, Maharashtra, India.

DOI: 10.59556/japi.72.0671

MeSH Terms: Humans, Sodium Potassium Chloride Symporter Inhibitors, Furosemide, Torsemide, Bumetanide, Heart Failure